Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial.

Summary: Doctors want to know exactly which breast cancer patients will get better when taking a specific drug called palbociclib. Right now, there is no simple test to predict this. Researchers looked at data from a clinical trial to find clues in patients' blood and tumors. While they didn't find a perfect, definitive test, they did discover that patients with certain gene changes (like a TP53 mutation) or higher amounts of tumor DNA in their blood did not respond as well to the treatment. This helpful information points scientists in the right direction for future research to find the best treatments for breast cancer!